prodisc C SK and prodisc C Vivo
Centinel Spine, LLC · Decision date Oct 10, 2025
What did the FDA approve?
FDA records P070001/S025 as a supplement to PMA P070001, with the supplement type “Panel Track”. The recorded decision is approval, dated Oct 10, 2025.
FDA approval order statement
The prodisc C SK and prodisc C Vivo are both indicated for use in skeletally mature patients for reconstruction of the disc from C3-C7 following discectomy at one or two contiguous levels for intractable radiculopathy (arm pain and/or a neurological deficit) with or without neck pain, or myelopathy due to abnormality localized to the level of the disc space and at least one of the following conditions confirmed by radiographic imaging (CT, MRI, X-rays): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), and/or visible loss of disc height as compared to adjacent levels. The prodisc C SK and prodisc C Vivo are implanted using an anterior approach. Patients should have failed at least 6 weeks of conservative treatment or demonstrated progressive signs or symptoms despite non-operative treatment prior to implantation of the prodisc C SK and prodisc C Vivo.
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Orthopedic
- Decision date
- Oct 10, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P070001/S025
- Regulatory pathway
- PMA supplement
- Applicant
- Centinel Spine, LLC
- Product code
- MJO
- Decision code
- APPR
- Decision date
- Oct 10, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, intervertebral disc.
- Applicant
- Centinel Spine, LLC
- Product code
- MJO
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P070001. Subsequent supplements may change the device or its indications.
FDA decision timeline
P070001 · Original PMA
PRODISC TM-C TOTAL DISC REPLACEMENT
P070001/S025 received
Application receipt date recorded by FDA.
P070001/S029 · Related supplement
prodisc C
P070001/S025 · FDA decision
Panel Track
P070001/S030 · Related supplement
prodisc C
P070001/S031 · Related supplement
prodisc C Nova
Timeline entries are records held by MedtechLedger for P070001. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P070001
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Centinel Spine, LLC | PMA approval | Dec 17, 2007 | FDA | |
prodisc CP070001/S029 | Centinel Spine, LLC | PMA supplement | Jul 30, 2025 | FDA |
prodisc CP070001/S030 | Centinel Spine, LLC | PMA supplement | Jan 15, 2026 | FDA |
prodisc C NovaP070001/S031 | Centinel Spine, LLC | PMA supplement | Sep 9, 2026 | FDA |
Explore the linked device profile
Other records with product code MJO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
BAGUERAC Cervical Disc ProsthesisP250042/S002 | Spineart USA, Inc. | PMA supplement | Sep 22, 2026 | FDA |
Synergy DiscP250028/S003 | Synergy Spine Solutions, Inc. | PMA supplement | Sep 17, 2026 | FDA |
| Highridge Medical, LLC | PMA supplement | Sep 16, 2026 | FDA | |
| Highridge Medical, LLC | PMA supplement | Sep 16, 2026 | FDA | |
BAGUERAC Cervical Disc ProsthesisP250042/S001 | Spineart USA, Inc. | PMA supplement | Aug 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Centinel Spine, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 900 Airport Rd., Suite 3b, West Chester, PA, 19380
Sources and methodology
- Original FDA record: P070001/S025
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






